Identification

Name
Palmitic Acid
Accession Number
DB03796  (EXPT01393, EXPT02607)
Type
Small Molecule
Groups
Experimental
Description

A common saturated fatty acid found in fats and waxes including olive oil, palm oil, and body lipids. [PubChem]

Structure
Thumb
Synonyms
  • 1-Hexyldecanoic Acid
  • 1-Pentadecanecarboxylic acid
  • FAT
  • Hexadecanoate
  • Hexadecanoic acid
  • Hexadecoic acid
  • Hexadecylic acid
  • Hexaectylic acid
  • Palmitate
  • Palmitinic acid
  • Palmitinsaeure
External IDs
EDENOR C 16-98-100 / FEMA NO. 2832 / HYDROFOL ACID 1690 / IMEX C 1498 / KORTACID 1698 / LOXIOL EP 278 / NSC-5030
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
Levovist - Pws IV (4g Granules /vial)Palmitic Acid (1 mg) + Galactose (999 mg)Powder, for solutionIntravenousBerlex Laboratories, Inc.1997-12-192003-06-26Canada
Sha-lemPalmitic Acid (7.25 g/30mL) + Bismuth Subcarbonate (1.89 g/30mL) + Boric acid (.95 g/30mL) + Oleic Acid (14.5 g/30mL) + Stearic acid (7.25 g/30mL)OintmentTopicalShalem Products, Inc.1992-05-08Not applicableUs
Categories
UNII
2V16EO95H1
CAS number
57-10-3
Weight
Average: 256.4241
Monoisotopic: 256.240230268
Chemical Formula
C16H32O2
InChI Key
IPCSVZSSVZVIGE-UHFFFAOYSA-N
InChI
InChI=1S/C16H32O2/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16(17)18/h2-15H2,1H3,(H,17,18)
IUPAC Name
hexadecanoic acid
SMILES
CCCCCCCCCCCCCCCC(O)=O

Pharmacology

Indication
Not Available
Structured Indications
Not Available
Pharmacodynamics

Palmitic acid is the first fatty acid produced during lipogenesis (fatty acid synthesis) and from which longer fatty acids can be produced. Palmitate negatively feeds back on acetyl-CoA carboxylase (ACC) which is responsible for converting acetyl-ACP to malonyl-ACP on the growing acyl chain, thus preventing further palmitate generation

Mechanism of action
TargetActionsOrganism
URhodopsinNot AvailableHuman
USEC14-like protein 2Not AvailableHuman
UPalmitoyl-protein thioesterase 1Not AvailableHuman
UMyelin P2 proteinNot AvailableHuman
UGlycodelinNot AvailableHuman
UHepatocyte nuclear factor 4-gammaNot AvailableHuman
ULipid binding proteinNot AvailableGeobacillus stearothermophilus
UCytochrome P450 2C8Not AvailableHuman
UTrafficking protein particle complex subunit 3Not AvailableHuman
UFatty acid-binding protein TM_1468Not AvailableThermotoga maritima (strain ATCC 43589 / MSB8 / DSM 3109 / JCM 10099)
UAlpha-lactalbuminNot AvailableHuman
UPeroxisome proliferator-activated receptor alphaNot AvailableHuman
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity

Acute oral toxicity (LD50) in rat is >10000 mg/kg

Affected organisms
Not Available
Pathways
PathwayCategory
Glycerolipid MetabolismMetabolic
Alendronate Action PathwayDrug action
Zoledronate Action PathwayDrug action
Cerebrotendinous Xanthomatosis (CTX)Disease
Fatty Acid BiosynthesisMetabolic
Wolman diseaseDisease
Long chain acyl-CoA dehydrogenase deficiency (LCAD)Disease
Fatty Acid Elongation In MitochondriaMetabolic
Cerivastatin Action PathwayDrug action
Pamidronate Action PathwayDrug action
Atorvastatin Action PathwayDrug action
Cholesteryl ester storage diseaseDisease
Mevalonic aciduriaDisease
Trifunctional protein deficiencyDisease
Rosuvastatin Action PathwayDrug action
Fluvastatin Action PathwayDrug action
Short Chain Acyl CoA Dehydrogenase Deficiency (SCAD Deficiency)Disease
CHILD SyndromeDisease
Hyper-IgD syndromeDisease
Carnitine palmitoyl transferase deficiency (I)Disease
Medium chain acyl-coa dehydrogenase deficiency (MCAD)Disease
27-Hydroxylase DeficiencyDisease
Pravastatin Action PathwayDrug action
Risedronate Action PathwayDrug action
Glutaric Aciduria Type IDisease
Glycerol Kinase DeficiencyDisease
HypercholesterolemiaDisease
Congenital Bile Acid Synthesis Defect Type IIDisease
Zellweger SyndromeDisease
Congenital Bile Acid Synthesis Defect Type IIIDisease
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
AcebutololThe serum concentration of Acebutolol can be increased when it is combined with Palmitic Acid.Approved
AcetaminophenThe serum concentration of Acetaminophen can be increased when it is combined with Palmitic Acid.Approved
Acetylsalicylic acidThe serum concentration of Acetylsalicylic acid can be increased when it is combined with Palmitic Acid.Approved, Vet Approved
AfatinibThe serum concentration of Afatinib can be increased when it is combined with Palmitic Acid.Approved
AldosteroneThe serum concentration of Aldosterone can be increased when it is combined with Palmitic Acid.Experimental
AlitretinoinThe serum concentration of Alitretinoin can be increased when it is combined with Palmitic Acid.Approved, Investigational
AmbrisentanThe serum concentration of Ambrisentan can be increased when it is combined with Palmitic Acid.Approved, Investigational
AmitriptylineThe serum concentration of Amitriptyline can be increased when it is combined with Palmitic Acid.Approved
ApixabanThe serum concentration of Apixaban can be increased when it is combined with Palmitic Acid.Approved
Arsenic trioxideThe serum concentration of Arsenic trioxide can be increased when it is combined with Palmitic Acid.Approved, Investigational
AtazanavirThe serum concentration of Atazanavir can be increased when it is combined with Palmitic Acid.Approved, Investigational
AtenololThe serum concentration of Atenolol can be increased when it is combined with Palmitic Acid.Approved
AxitinibThe serum concentration of Axitinib can be increased when it is combined with Palmitic Acid.Approved, Investigational
BelinostatThe serum concentration of Belinostat can be increased when it is combined with Palmitic Acid.Approved, Investigational
BetamethasoneThe serum concentration of Betamethasone can be increased when it is combined with Palmitic Acid.Approved, Vet Approved
BoceprevirThe serum concentration of Boceprevir can be increased when it is combined with Palmitic Acid.Withdrawn
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Palmitic Acid.Approved
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Palmitic Acid.Approved
BromocriptineThe serum concentration of Bromocriptine can be increased when it is combined with Palmitic Acid.Approved, Investigational
CabazitaxelThe serum concentration of Cabazitaxel can be increased when it is combined with Palmitic Acid.Approved
CaffeineThe serum concentration of Caffeine can be increased when it is combined with Palmitic Acid.Approved
CamptothecinThe serum concentration of Camptothecin can be increased when it is combined with Palmitic Acid.Experimental
CanagliflozinThe serum concentration of Canagliflozin can be increased when it is combined with Palmitic Acid.Approved
CarbamazepineThe serum concentration of Carbamazepine can be increased when it is combined with Palmitic Acid.Approved, Investigational
CarfilzomibThe serum concentration of Carfilzomib can be increased when it is combined with Palmitic Acid.Approved
CeritinibThe serum concentration of Ceritinib can be increased when it is combined with Palmitic Acid.Approved
CerivastatinThe serum concentration of Cerivastatin can be increased when it is combined with Palmitic Acid.Withdrawn
ChlorpromazineThe serum concentration of Chlorpromazine can be increased when it is combined with Palmitic Acid.Approved, Vet Approved
CimetidineThe serum concentration of Cimetidine can be increased when it is combined with Palmitic Acid.Approved
CiprofloxacinThe serum concentration of Ciprofloxacin can be increased when it is combined with Palmitic Acid.Approved, Investigational
CisplatinThe serum concentration of Cisplatin can be increased when it is combined with Palmitic Acid.Approved
CitalopramThe serum concentration of Citalopram can be increased when it is combined with Palmitic Acid.Approved
ClarithromycinThe serum concentration of Clarithromycin can be increased when it is combined with Palmitic Acid.Approved
ClobazamThe serum concentration of Clobazam can be increased when it is combined with Palmitic Acid.Approved, Illicit
ClomifeneThe serum concentration of Clomifene can be increased when it is combined with Palmitic Acid.Approved, Investigational
ClonidineThe serum concentration of Clonidine can be increased when it is combined with Palmitic Acid.Approved
ClopidogrelThe serum concentration of Clopidogrel can be increased when it is combined with Palmitic Acid.Approved, Nutraceutical
ClozapineThe serum concentration of Clozapine can be increased when it is combined with Palmitic Acid.Approved
CobimetinibThe serum concentration of Cobimetinib can be increased when it is combined with Palmitic Acid.Approved
ColchicineThe serum concentration of Colchicine can be increased when it is combined with Palmitic Acid.Approved
Conjugated estrogensThe serum concentration of Conjugated estrogens can be increased when it is combined with Palmitic Acid.Approved
CopanlisibThe serum concentration of Copanlisib can be increased when it is combined with Palmitic Acid.Approved
CrizotinibThe serum concentration of Crizotinib can be increased when it is combined with Palmitic Acid.Approved
CyclosporineThe serum concentration of Cyclosporine can be increased when it is combined with Palmitic Acid.Approved, Investigational, Vet Approved
Dabigatran etexilateThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Palmitic Acid.Approved
DabrafenibThe serum concentration of Dabrafenib can be increased when it is combined with Palmitic Acid.Approved
DactinomycinThe serum concentration of Dactinomycin can be increased when it is combined with Palmitic Acid.Approved
DapagliflozinThe serum concentration of Dapagliflozin can be increased when it is combined with Palmitic Acid.Approved
DasatinibThe serum concentration of Dasatinib can be increased when it is combined with Palmitic Acid.Approved, Investigational
DaunorubicinThe serum concentration of Daunorubicin can be increased when it is combined with Palmitic Acid.Approved
DebrisoquinThe serum concentration of Debrisoquin can be increased when it is combined with Palmitic Acid.Approved
DexamethasoneThe serum concentration of Dexamethasone can be increased when it is combined with Palmitic Acid.Approved, Investigational, Vet Approved
DiazepamThe serum concentration of Diazepam can be increased when it is combined with Palmitic Acid.Approved, Illicit, Vet Approved
DiethylstilbestrolThe serum concentration of Diethylstilbestrol can be increased when it is combined with Palmitic Acid.Approved
DigitoxinThe serum concentration of Digitoxin can be increased when it is combined with Palmitic Acid.Approved
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Palmitic Acid.Approved
DihydrotestosteroneThe serum concentration of Dihydrotestosterone can be increased when it is combined with Palmitic Acid.Illicit
DiltiazemThe serum concentration of Diltiazem can be increased when it is combined with Palmitic Acid.Approved
DipyridamoleThe serum concentration of Dipyridamole can be increased when it is combined with Palmitic Acid.Approved
DocetaxelThe serum concentration of Docetaxel can be increased when it is combined with Palmitic Acid.Approved, Investigational
DomperidoneThe serum concentration of Domperidone can be increased when it is combined with Palmitic Acid.Approved, Investigational, Vet Approved
DoxorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Palmitic Acid.Approved, Investigational
EdoxabanThe serum concentration of Edoxaban can be increased when it is combined with Palmitic Acid.Approved
ElbasvirThe serum concentration of Elbasvir can be increased when it is combined with Palmitic Acid.Approved
EletriptanThe serum concentration of Eletriptan can be increased when it is combined with Palmitic Acid.Approved, Investigational
EnasidenibThe serum concentration of Enasidenib can be increased when it is combined with Palmitic Acid.Approved
EpinastineThe serum concentration of Epinastine can be increased when it is combined with Palmitic Acid.Approved, Investigational
ErlotinibThe serum concentration of Erlotinib can be increased when it is combined with Palmitic Acid.Approved, Investigational
ErythromycinThe serum concentration of Erythromycin can be increased when it is combined with Palmitic Acid.Approved, Vet Approved
EstradiolThe serum concentration of Estradiol can be increased when it is combined with Palmitic Acid.Approved, Investigational, Vet Approved
EstriolThe serum concentration of Estriol can be increased when it is combined with Palmitic Acid.Approved, Vet Approved
EstroneThe serum concentration of Estrone can be increased when it is combined with Palmitic Acid.Approved
Ethinyl EstradiolThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Palmitic Acid.Approved
EtoposideThe serum concentration of Etoposide can be increased when it is combined with Palmitic Acid.Approved
EverolimusThe serum concentration of Everolimus can be increased when it is combined with Palmitic Acid.Approved
EzetimibeThe serum concentration of Ezetimibe can be increased when it is combined with Palmitic Acid.Approved
FesoterodineThe serum concentration of Fesoterodine can be increased when it is combined with Palmitic Acid.Approved
FexofenadineThe serum concentration of Fexofenadine can be increased when it is combined with Palmitic Acid.Approved
FidaxomicinThe serum concentration of Fidaxomicin can be increased when it is combined with Palmitic Acid.Approved
Fluticasone furoateThe serum concentration of Fluticasone furoate can be increased when it is combined with Palmitic Acid.Approved
GefitinibThe serum concentration of Gefitinib can be increased when it is combined with Palmitic Acid.Approved, Investigational
GemcitabineThe serum concentration of Gemcitabine can be increased when it is combined with Palmitic Acid.Approved
GlecaprevirThe serum concentration of Glecaprevir can be increased when it is combined with Palmitic Acid.Approved
GrazoprevirThe serum concentration of Grazoprevir can be increased when it is combined with Palmitic Acid.Approved
GrepafloxacinThe serum concentration of Grepafloxacin can be increased when it is combined with Palmitic Acid.Withdrawn
HaloperidolThe serum concentration of Haloperidol can be increased when it is combined with Palmitic Acid.Approved
HydrocortisoneThe serum concentration of Hydrocortisone can be increased when it is combined with Palmitic Acid.Approved, Vet Approved
IbuprofenThe serum concentration of Ibuprofen can be increased when it is combined with Palmitic Acid.Approved
IdelalisibThe serum concentration of Idelalisib can be increased when it is combined with Palmitic Acid.Approved
ImatinibThe serum concentration of Imatinib can be increased when it is combined with Palmitic Acid.Approved
ImipramineThe serum concentration of Imipramine can be increased when it is combined with Palmitic Acid.Approved
IndacaterolThe serum concentration of Indacaterol can be increased when it is combined with Palmitic Acid.Approved
IndinavirThe serum concentration of Indinavir can be increased when it is combined with Palmitic Acid.Approved
IndomethacinThe serum concentration of Indomethacin can be increased when it is combined with Palmitic Acid.Approved, Investigational
Inotuzumab ozogamicinThe serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Palmitic Acid.Approved
IrinotecanThe serum concentration of Irinotecan can be increased when it is combined with Palmitic Acid.Approved, Investigational
IvermectinThe serum concentration of Ivermectin can be increased when it is combined with Palmitic Acid.Approved, Vet Approved
KetazolamThe serum concentration of Ketazolam can be increased when it is combined with Palmitic Acid.Approved
KetoconazoleThe serum concentration of Ketoconazole can be increased when it is combined with Palmitic Acid.Approved, Investigational
LamivudineThe serum concentration of Lamivudine can be increased when it is combined with Palmitic Acid.Approved, Investigational
LamotrigineThe serum concentration of Lamotrigine can be increased when it is combined with Palmitic Acid.Approved, Investigational
LansoprazoleThe serum concentration of Lansoprazole can be increased when it is combined with Palmitic Acid.Approved, Investigational
LedipasvirThe serum concentration of Ledipasvir can be increased when it is combined with Palmitic Acid.Approved
LenalidomideThe serum concentration of Lenalidomide can be increased when it is combined with Palmitic Acid.Approved
LenvatinibThe serum concentration of Lenvatinib can be increased when it is combined with Palmitic Acid.Approved
LevetiracetamThe serum concentration of Levetiracetam can be increased when it is combined with Palmitic Acid.Approved, Investigational
LevofloxacinThe serum concentration of Levofloxacin can be increased when it is combined with Palmitic Acid.Approved, Investigational
LevomilnacipranThe serum concentration of Levomilnacipran can be increased when it is combined with Palmitic Acid.Approved
LinagliptinThe serum concentration of Linagliptin can be increased when it is combined with Palmitic Acid.Approved
LoperamideThe serum concentration of Loperamide can be increased when it is combined with Palmitic Acid.Approved
LosartanThe serum concentration of Losartan can be increased when it is combined with Palmitic Acid.Approved
MannitolThe serum concentration of Mannitol can be increased when it is combined with Palmitic Acid.Approved, Investigational
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Palmitic Acid.Approved
MethylprednisoloneThe serum concentration of Methylprednisolone can be increased when it is combined with Palmitic Acid.Approved, Vet Approved
MetoprololThe serum concentration of Metoprolol can be increased when it is combined with Palmitic Acid.Approved, Investigational
MidazolamThe serum concentration of Midazolam can be increased when it is combined with Palmitic Acid.Approved, Illicit
MirabegronThe serum concentration of Mirabegron can be increased when it is combined with Palmitic Acid.Approved
MitoxantroneThe serum concentration of Mitoxantrone can be increased when it is combined with Palmitic Acid.Approved, Investigational
MorphineThe serum concentration of Morphine can be increased when it is combined with Palmitic Acid.Approved, Investigational
Mycophenolate mofetilThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Palmitic Acid.Approved, Investigational
NadololThe serum concentration of Nadolol can be increased when it is combined with Palmitic Acid.Approved
NaloxegolThe serum concentration of Naloxegol can be increased when it is combined with Palmitic Acid.Approved
NaloxoneThe serum concentration of Naloxone can be increased when it is combined with Palmitic Acid.Approved, Vet Approved
NelfinavirThe serum concentration of Nelfinavir can be increased when it is combined with Palmitic Acid.Approved
NicardipineThe serum concentration of Nicardipine can be increased when it is combined with Palmitic Acid.Approved
NifedipineThe serum concentration of Nifedipine can be increased when it is combined with Palmitic Acid.Approved
NilotinibThe serum concentration of Nilotinib can be increased when it is combined with Palmitic Acid.Approved, Investigational
NintedanibThe serum concentration of Nintedanib can be increased when it is combined with Palmitic Acid.Approved
NizatidineThe serum concentration of Nizatidine can be increased when it is combined with Palmitic Acid.Approved
OdanacatibThe serum concentration of Odanacatib can be increased when it is combined with Palmitic Acid.Investigational
OlanzapineThe serum concentration of Olanzapine can be increased when it is combined with Palmitic Acid.Approved, Investigational
OmbitasvirThe serum concentration of Ombitasvir can be increased when it is combined with Palmitic Acid.Approved
OsimertinibThe serum concentration of Osimertinib can be increased when it is combined with Palmitic Acid.Approved
PaclitaxelThe serum concentration of Paclitaxel can be increased when it is combined with Palmitic Acid.Approved, Vet Approved
PanobinostatThe serum concentration of Panobinostat can be increased when it is combined with Palmitic Acid.Approved, Investigational
PazopanibThe serum concentration of Pazopanib can be increased when it is combined with Palmitic Acid.Approved
PhenobarbitalThe serum concentration of Phenobarbital can be increased when it is combined with Palmitic Acid.Approved
PhenytoinThe serum concentration of Phenytoin can be increased when it is combined with Palmitic Acid.Approved, Vet Approved
PibrentasvirThe serum concentration of Pibrentasvir can be increased when it is combined with Palmitic Acid.Approved
PitavastatinThe serum concentration of Pitavastatin can be increased when it is combined with Palmitic Acid.Approved
PomalidomideThe serum concentration of Pomalidomide can be increased when it is combined with Palmitic Acid.Approved
PonatinibThe serum concentration of Ponatinib can be increased when it is combined with Palmitic Acid.Approved
PravastatinThe serum concentration of Pravastatin can be increased when it is combined with Palmitic Acid.Approved
PrazosinThe serum concentration of Prazosin can be increased when it is combined with Palmitic Acid.Approved
PrednisoloneThe serum concentration of Prednisolone can be increased when it is combined with Palmitic Acid.Approved, Vet Approved
PrednisoneThe serum concentration of Prednisone can be increased when it is combined with Palmitic Acid.Approved, Vet Approved
ProgesteroneThe serum concentration of Progesterone can be increased when it is combined with Palmitic Acid.Approved, Vet Approved
PropranololThe serum concentration of Propranolol can be increased when it is combined with Palmitic Acid.Approved, Investigational
PrucaloprideThe serum concentration of Prucalopride can be increased when it is combined with Palmitic Acid.Approved
QuetiapineThe serum concentration of Quetiapine can be increased when it is combined with Palmitic Acid.Approved
QuinidineThe serum concentration of Quinidine can be increased when it is combined with Palmitic Acid.Approved
QuinineThe serum concentration of Quinine can be increased when it is combined with Palmitic Acid.Approved
RanitidineThe serum concentration of Ranitidine can be increased when it is combined with Palmitic Acid.Approved
RanolazineThe serum concentration of Ranolazine can be increased when it is combined with Palmitic Acid.Approved, Investigational
ReserpineThe serum concentration of Reserpine can be increased when it is combined with Palmitic Acid.Approved
RifampicinThe serum concentration of Rifampicin can be increased when it is combined with Palmitic Acid.Approved
RifaximinThe serum concentration of Rifaximin can be increased when it is combined with Palmitic Acid.Approved, Investigational
RisperidoneThe serum concentration of Risperidone can be increased when it is combined with Palmitic Acid.Approved, Investigational
RitonavirThe serum concentration of Ritonavir can be increased when it is combined with Palmitic Acid.Approved, Investigational
RivaroxabanThe serum concentration of Rivaroxaban can be increased when it is combined with Palmitic Acid.Approved
RomidepsinThe serum concentration of Romidepsin can be increased when it is combined with Palmitic Acid.Approved, Investigational
Salicylic acidThe serum concentration of Salicylic acid can be increased when it is combined with Palmitic Acid.Approved, Vet Approved
SaquinavirThe serum concentration of Saquinavir can be increased when it is combined with Palmitic Acid.Approved, Investigational
SelexipagThe serum concentration of Selexipag can be increased when it is combined with Palmitic Acid.Approved
SilodosinThe serum concentration of Silodosin can be increased when it is combined with Palmitic Acid.Approved
SimeprevirThe serum concentration of Simeprevir can be increased when it is combined with Palmitic Acid.Approved
SitagliptinThe serum concentration of Sitagliptin can be increased when it is combined with Palmitic Acid.Approved, Investigational
SofosbuvirThe serum concentration of Sofosbuvir can be increased when it is combined with Palmitic Acid.Approved
SorafenibThe serum concentration of Sorafenib can be increased when it is combined with Palmitic Acid.Approved, Investigational
SparfloxacinThe serum concentration of Sparfloxacin can be increased when it is combined with Palmitic Acid.Approved
SphingosineThe serum concentration of Sphingosine can be increased when it is combined with Palmitic Acid.Experimental
TacrolimusThe serum concentration of Tacrolimus can be increased when it is combined with Palmitic Acid.Approved, Investigational
TamoxifenThe serum concentration of Tamoxifen can be increased when it is combined with Palmitic Acid.Approved
Taurocholic AcidThe serum concentration of Taurocholic Acid can be increased when it is combined with Palmitic Acid.Experimental
Technetium Tc-99m sestamibiThe serum concentration of Technetium Tc-99m sestamibi can be increased when it is combined with Palmitic Acid.Approved
TelaprevirThe serum concentration of Telaprevir can be increased when it is combined with Palmitic Acid.Withdrawn
TemsirolimusThe serum concentration of Temsirolimus can be increased when it is combined with Palmitic Acid.Approved
TicagrelorThe serum concentration of Ticagrelor can be increased when it is combined with Palmitic Acid.Approved
TimololThe serum concentration of Timolol can be increased when it is combined with Palmitic Acid.Approved
TolvaptanThe serum concentration of Tolvaptan can be increased when it is combined with Palmitic Acid.Approved
TopotecanThe serum concentration of Topotecan can be increased when it is combined with Palmitic Acid.Approved, Investigational
ToremifeneThe serum concentration of Toremifene can be increased when it is combined with Palmitic Acid.Approved, Investigational
Trastuzumab emtansineThe serum concentration of Trastuzumab emtansine can be increased when it is combined with Palmitic Acid.Approved
UlipristalThe serum concentration of Ulipristal can be increased when it is combined with Palmitic Acid.Approved
UmeclidiniumThe serum concentration of Umeclidinium can be increased when it is combined with Palmitic Acid.Approved
VecuroniumThe serum concentration of Vecuronium can be increased when it is combined with Palmitic Acid.Approved
VelpatasvirThe serum concentration of Velpatasvir can be increased when it is combined with Palmitic Acid.Approved
VenetoclaxThe serum concentration of Venetoclax can be increased when it is combined with Palmitic Acid.Approved
VenlafaxineThe serum concentration of Venlafaxine can be increased when it is combined with Palmitic Acid.Approved
VerapamilThe serum concentration of Verapamil can be increased when it is combined with Palmitic Acid.Approved
VinblastineThe serum concentration of Vinblastine can be increased when it is combined with Palmitic Acid.Approved
VincristineThe serum concentration of Vincristine can be increased when it is combined with Palmitic Acid.Approved, Investigational
VismodegibThe serum concentration of Vismodegib can be increased when it is combined with Palmitic Acid.Approved
VoxilaprevirThe serum concentration of Voxilaprevir can be increased when it is combined with Palmitic Acid.Approved
ZidovudineThe serum concentration of Zidovudine can be increased when it is combined with Palmitic Acid.Approved
Food Interactions
Not Available

References

Synthesis Reference

Walter R. Fehr, Earl G. Hammond, "Elevated palmitic acid production in soybeans." U.S. Patent US5750846, issued February, 1997.

US5750846
General References
Not Available
External Links
Human Metabolome Database
HMDB00220
KEGG Drug
D05341
KEGG Compound
C00249
PubChem Compound
985
PubChem Substance
46506400
ChemSpider
960
BindingDB
50152850
ChEBI
15756
ChEMBL
CHEMBL82293
IUPHAR
1055
Guide to Pharmacology
GtP Drug Page
HET
PLM
Wikipedia
Palmitic_Acid
PDB Entries
1aca / 1b0o / 1b56 / 1be2 / 1cov / 1e12 / 1e7h / 1eh5 / 1ev1 / 1gxa
show 262 more
MSDS
Download (73 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
Not AvailableCompletedNot AvailableRespiratory Distress Syndrome, Newborn1
Not AvailableCompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections2
Not AvailableRecruitingSupportive CareCholestasis / Liver Diseases1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
FormRouteStrength
Powder, for solutionIntravenous
OintmentTopical
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)61.8 °CPhysProp
boiling point (°C)351.5 °CPhysProp
water solubility0.04 mg/L (at 25 °C)ROBB.ID (1966)
logP7.17SANGSTER (1993)
logS-6.81ADME Research, USCD
Predicted Properties
PropertyValueSource
Water Solubility0.000407 mg/mLALOGPS
logP7.23ALOGPS
logP6.26ChemAxon
logS-5.8ALOGPS
pKa (Strongest Acidic)4.95ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area37.3 Å2ChemAxon
Rotatable Bond Count14ChemAxon
Refractivity77.08 m3·mol-1ChemAxon
Polarizability34.36 Å3ChemAxon
Number of Rings0ChemAxon
Bioavailability0ChemAxon
Rule of FiveNoChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9888
Blood Brain Barrier+0.9488
Caco-2 permeable+0.8326
P-glycoprotein substrateNon-substrate0.6321
P-glycoprotein inhibitor INon-inhibitor0.9598
P-glycoprotein inhibitor IINon-inhibitor0.9277
Renal organic cation transporterNon-inhibitor0.9266
CYP450 2C9 substrateNon-substrate0.7886
CYP450 2D6 substrateNon-substrate0.8956
CYP450 3A4 substrateNon-substrate0.6982
CYP450 1A2 substrateInhibitor0.8326
CYP450 2C9 inhibitorNon-inhibitor0.8808
CYP450 2D6 inhibitorNon-inhibitor0.9554
CYP450 2C19 inhibitorNon-inhibitor0.9578
CYP450 3A4 inhibitorNon-inhibitor0.9484
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9647
Ames testNon AMES toxic0.9865
CarcinogenicityNon-carcinogens0.6452
BiodegradationReady biodegradable0.8795
Rat acute toxicity1.3275 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9322
hERG inhibition (predictor II)Non-inhibitor0.8868
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Download (10.5 KB)
Spectra
SpectrumSpectrum TypeSplash Key
GC-MS Spectrum - GC-EI-TOF (Pegasus III TOF-MS system, Leco; GC 6890, Agilent Technologies) (1 TMS)GC-MSsplash10-014i-0901000000-51ee83f9462d25fa4045
GC-MS Spectrum - GC-EI-TOF (Pegasus III TOF-MS system, Leco; GC 6890, Agilent Technologies) (1 TMS)GC-MSsplash10-0100-9700000000-3d8b6cf4736afa482b57
GC-MS Spectrum - GC-MS (1 TMS)GC-MSsplash10-0159-2901000000-fb423e89a78708021db1
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
GC-MS Spectrum - EI-BGC-MSsplash10-0abc-9110000000-6d7f0dbe5b588850b941
GC-MS Spectrum - GC-EI-TOFGC-MSsplash10-014i-0901000000-51ee83f9462d25fa4045
GC-MS Spectrum - GC-EI-TOFGC-MSsplash10-0100-9700000000-3d8b6cf4736afa482b57
GC-MS Spectrum - GC-MSGC-MSsplash10-0159-2901000000-fb423e89a78708021db1
GC-MS Spectrum - GC-MSGC-MSsplash10-0159-2901000000-fb423e89a78708021db1
GC-MS Spectrum - GC-EI-TOFGC-MSsplash10-014i-1900000000-d7638a578d846871e670
Mass Spectrum (Electron Ionization)MSsplash10-06xx-9100000000-7ac9cd088cb9cb9f7560
MS/MS Spectrum - Quattro_QQQ 10V, NegativeLC-MS/MSsplash10-0a4i-0090000000-39c3a0e17432781e9760
MS/MS Spectrum - Quattro_QQQ 25V, NegativeLC-MS/MSsplash10-0a4i-0090000000-8ec1a6953701fc22ce27
MS/MS Spectrum - Quattro_QQQ 40V, NegativeLC-MS/MSsplash10-0fba-9200000000-23c995bf81d5ef609489
MS/MS Spectrum - EI-B (HITACHI M-80) , PositiveLC-MS/MSsplash10-0abc-9110000000-12f1884d67998fb924a5
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSsplash10-000i-0090000000-26bb4965a56ab0e82b49
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSsplash10-06rj-5790000000-251700f3edf9a5af04cd
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSsplash10-052f-9600000000-5b75a67e276017f221b8
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSsplash10-000i-0090000000-26bb4965a56ab0e82b49
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSsplash10-06rj-5790000000-251700f3edf9a5af04cd
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSsplash10-052f-9600000000-5b75a67e276017f221b8
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSsplash10-0a4i-0090000000-e4a4200bd25f8fa480cc
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSsplash10-0bti-1090000000-768a48058fc0a2d7a877
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSsplash10-0a4l-9320000000-c9714c7ffdc804bf9323
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSsplash10-0a4i-0090000000-e4a4200bd25f8fa480cc
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSsplash10-0bti-1090000000-768a48058fc0a2d7a877
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSsplash10-0a4l-9320000000-c9714c7ffdc804bf9323
MS/MS Spectrum - ESI-TOF , NegativeLC-MS/MSNot Available
MS/MS Spectrum - ESI-TOF 30V, NegativeLC-MS/MSNot Available
MS/MS Spectrum - ESI-TOF 10V, NegativeLC-MS/MSNot Available
MS/MS Spectrum - ESI-TOF 20V, NegativeLC-MS/MSNot Available
MS/MS Spectrum - ESI-TOF , NegativeLC-MS/MSNot Available
MS/MS Spectrum - ESI-TOF , NegativeLC-MS/MSNot Available
MS/MS Spectrum - ESI-TOF 30V, NegativeLC-MS/MSNot Available
MS/MS Spectrum - ESI-TOF 10V, NegativeLC-MS/MSNot Available
MS/MS Spectrum - ESI-TOF 20V, NegativeLC-MS/MSNot Available
MS/MS Spectrum - ESI-TOF , NegativeLC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-IT , negativeLC-MS/MSsplash10-0a4i-0090000000-223f4eff3e7317becc5f
MS/MS Spectrum - Linear Ion Trap , negativeLC-MS/MSsplash10-0a4i-0090000000-b8d2b3a35e69dec8d778
MS/MS Spectrum - Linear Ion Trap , negativeLC-MS/MSsplash10-0a4i-0090000000-f22762c18b3f60b84574
MS/MS Spectrum - Linear Ion Trap , negativeLC-MS/MSsplash10-06di-0060900000-1ee2cc4eeef223b6220d
MS/MS Spectrum - Linear Ion Trap , negativeLC-MS/MSsplash10-06di-0070900000-639764620ee4d4bf831d
LC-MS/MS Spectrum - LC-ESI-TOF , negativeLC-MS/MSsplash10-0a4i-0090000000-c3f9f4d5c336137b7fcf
LC-MS/MS Spectrum - LC-ESI-TOF , negativeLC-MS/MSsplash10-0a4i-0090000000-47919da3faa8e0f52bbc
LC-MS/MS Spectrum - LC-ESI-TOF , negativeLC-MS/MSsplash10-0a4i-0090000000-fdd9e98416da12470fe9
MS/MS Spectrum - Linear Ion Trap , positiveLC-MS/MSsplash10-0a4i-0190000000-52c7106f2cfc09665c35
MS/MS Spectrum - Linear Ion Trap , positiveLC-MS/MSsplash10-0a4i-0190000000-c199865dcd8bfe2fdc8c
1H NMR Spectrum1D NMRNot Applicable
13C NMR Spectrum1D NMRNot Applicable
1H NMR Spectrum1D NMRNot Applicable
13C NMR Spectrum1D NMRNot Applicable
[1H,13C] 2D NMR Spectrum2D NMRNot Applicable

Taxonomy

Description
This compound belongs to the class of organic compounds known as long-chain fatty acids. These are fatty acids with an aliphatic tail that contains between 13 and 21 carbon atoms.
Kingdom
Organic compounds
Super Class
Lipids and lipid-like molecules
Class
Fatty Acyls
Sub Class
Fatty acids and conjugates
Direct Parent
Long-chain fatty acids
Alternative Parents
Straight chain fatty acids / Monocarboxylic acids and derivatives / Carboxylic acids / Organic oxides / Hydrocarbon derivatives / Carbonyl compounds
Substituents
Long-chain fatty acid / Straight chain fatty acid / Monocarboxylic acid or derivatives / Carboxylic acid / Carboxylic acid derivative / Organic oxygen compound / Organic oxide / Hydrocarbon derivative / Organooxygen compound / Carbonyl group
Molecular Framework
Aliphatic acyclic compounds
External Descriptors
long-chain fatty acid, straight-chain saturated fatty acid (CHEBI:15756) / Straight chain fatty acids, Saturated fatty acids (C00249) / Straight chain fatty acids (LMFA01010001)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Photoreceptor activity
Specific Function
Photoreceptor required for image-forming vision at low light intensity. Required for photoreceptor cell viability after birth. Light-induced isomerization of 11-cis to all-trans retinal triggers a ...
Gene Name
RHO
Uniprot ID
P08100
Uniprot Name
Rhodopsin
Molecular Weight
38892.335 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
  3. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [PubMed:10592235]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Vitamin e binding
Specific Function
Carrier protein. Binds to some hydrophobic molecules and promotes their transfer between the different cellular sites. Binds with high affinity to alpha-tocopherol. Also binds with a weaker affinit...
Gene Name
SEC14L2
Uniprot ID
O76054
Uniprot Name
SEC14-like protein 2
Molecular Weight
46144.9 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Palmitoyl-coa hydrolase activity
Specific Function
Removes thioester-linked fatty acyl groups such as palmitate from modified cysteine residues in proteins or peptides during lysosomal degradation. Prefers acyl chain lengths of 14 to 18 carbons.
Gene Name
PPT1
Uniprot ID
P50897
Uniprot Name
Palmitoyl-protein thioesterase 1
Molecular Weight
34193.245 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
  3. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [PubMed:10592235]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Transporter activity
Specific Function
May play a role in lipid transport protein in Schwann cells. May bind cholesterol.
Gene Name
PMP2
Uniprot ID
P02689
Uniprot Name
Myelin P2 protein
Molecular Weight
14909.305 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
  3. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [PubMed:10592235]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Small molecule binding
Specific Function
This protein is, quantitatively, the main protein synthesized and secreted in the endometrium from mid-luteal phase of the menstrual cycle and during the first semester of pregnancy.
Gene Name
PAEP
Uniprot ID
P09466
Uniprot Name
Glycodelin
Molecular Weight
20624.015 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
  3. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [PubMed:10592235]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Zinc ion binding
Specific Function
Transcription factor. Has a lower transcription activation potential than HNF4-alpha.
Gene Name
HNF4G
Uniprot ID
Q14541
Uniprot Name
Hepatocyte nuclear factor 4-gamma
Molecular Weight
45876.235 Da
Kind
Protein
Organism
Geobacillus stearothermophilus
Pharmacological action
Unknown
General Function
Lipid binding
Specific Function
Not Available
Gene Name
Not Available
Uniprot ID
P83812
Uniprot Name
Lipid binding protein
Molecular Weight
32173.81 Da
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2C8
Uniprot ID
P10632
Uniprot Name
Cytochrome P450 2C8
Molecular Weight
55824.275 Da
References
  1. Schoch GA, Yano JK, Wester MR, Griffin KJ, Stout CD, Johnson EF: Structure of human microsomal cytochrome P450 2C8. Evidence for a peripheral fatty acid binding site. J Biol Chem. 2004 Mar 5;279(10):9497-503. Epub 2003 Dec 15. [PubMed:14676196]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Not Available
Specific Function
May play a role in vesicular transport from endoplasmic reticulum to Golgi.
Gene Name
TRAPPC3
Uniprot ID
O43617
Uniprot Name
Trafficking protein particle complex subunit 3
Molecular Weight
20273.915 Da
Kind
Protein
Organism
Thermotoga maritima (strain ATCC 43589 / MSB8 / DSM 3109 / JCM 10099)
Pharmacological action
Unknown
General Function
Lipid binding
Specific Function
Binds long-chain fatty acids, such as palmitate, and may play a role in lipid transport or fatty acid metabolism.
Gene Name
Not Available
Uniprot ID
Q9X1H9
Uniprot Name
Fatty acid-binding protein TM_1468
Molecular Weight
32574.335 Da
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Lactose synthase activity
Specific Function
Regulatory subunit of lactose synthase, changes the substrate specificity of galactosyltransferase in the mammary gland making glucose a good acceptor substrate for this enzyme. This enables LS to ...
Gene Name
LALBA
Uniprot ID
P00709
Uniprot Name
Alpha-lactalbumin
Molecular Weight
16224.695 Da
References
  1. Barbana C, Perez MD, Pocovi C, Sanchez L, Wehbi Z: Interaction of human alpha-lactalbumin with fatty acids: determination of binding parameters. Biochemistry (Mosc). 2008 Jun;73(6):711-6. [PubMed:18620538]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Zinc ion binding
Specific Function
Ligand-activated transcription factor. Key regulator of lipid metabolism. Activated by the endogenous ligand 1-palmitoyl-2-oleoyl-sn-glycerol-3-phosphocholine (16:0/18:1-GPC). Activated by oleyleth...
Gene Name
PPARA
Uniprot ID
Q07869
Uniprot Name
Peroxisome proliferator-activated receptor alpha
Molecular Weight
52224.595 Da
References
  1. Murakami K, Ide T, Suzuki M, Mochizuki T, Kadowaki T: Evidence for direct binding of fatty acids and eicosanoids to human peroxisome proliferators-activated receptor alpha. Biochem Biophys Res Commun. 1999 Jul 14;260(3):609-13. [PubMed:10403814]

Carriers

Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Toxic substance binding
Specific Function
Serum albumin, the main protein of plasma, has a good binding capacity for water, Ca(2+), Na(+), K(+), fatty acids, hormones, bilirubin and drugs. Its main function is the regulation of the colloid...
Gene Name
ALB
Uniprot ID
P02768
Uniprot Name
Serum albumin
Molecular Weight
69365.94 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
  3. Simard JR, Zunszain PA, Hamilton JA, Curry S: Location of high and low affinity fatty acid binding sites on human serum albumin revealed by NMR drug-competition analysis. J Mol Biol. 2006 Aug 11;361(2):336-51. Epub 2006 Jun 30. [PubMed:16844140]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Transporter activity
Specific Function
Lipid transport protein in adipocytes. Binds both long chain fatty acids and retinoic acid. Delivers long-chain fatty acids and retinoic acid to their cognate receptors in the nucleus (By similarity).
Gene Name
FABP4
Uniprot ID
P15090
Uniprot Name
Fatty acid-binding protein, adipocyte
Molecular Weight
14718.815 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
  3. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [PubMed:10592235]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Transporter activity
Specific Function
High specificity for fatty acids. Highest affinity for C18 chain length. Decreasing the chain length or introducing double bonds reduces the affinity. May be involved in keratinocyte differentiation.
Gene Name
FABP5
Uniprot ID
Q01469
Uniprot Name
Fatty acid-binding protein, epidermal
Molecular Weight
15164.36 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Oleic acid binding
Specific Function
FABP are thought to play a role in the intracellular transport of long-chain fatty acids and their acyl-CoA esters.
Gene Name
FABP3
Uniprot ID
P05413
Uniprot Name
Fatty acid-binding protein, heart
Molecular Weight
14857.93 Da
References
  1. Zanotti G, Scapin G, Spadon P, Veerkamp JH, Sacchettini JC: Three-dimensional structure of recombinant human muscle fatty acid-binding protein. J Biol Chem. 1992 Sep 15;267(26):18541-50. [PubMed:1526991]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Transporter activity
Specific Function
FABP are thought to play a role in the intracellular transport of long-chain fatty acids and their acyl-CoA esters. FABP2 is probably involved in triglyceride-rich lipoprotein synthesis. Binds satu...
Gene Name
FABP2
Uniprot ID
P12104
Uniprot Name
Fatty acid-binding protein, intestinal
Molecular Weight
15207.165 Da
References
  1. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [PubMed:10592235]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Xenobiotic-transporting atpase activity
Specific Function
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name
ABCB1
Uniprot ID
P08183
Uniprot Name
Multidrug resistance protein 1
Molecular Weight
141477.255 Da
References
  1. Konishi T, Satsu H, Hatsugai Y, Aizawa K, Inakuma T, Nagata S, Sakuda SH, Nagasawa H, Shimizu M: Inhibitory effect of a bitter melon extract on the P-glycoprotein activity in intestinal Caco-2 cells. Br J Pharmacol. 2004 Oct;143(3):379-87. Epub 2004 Sep 6. [PubMed:15351776]

Drug created on June 13, 2005 07:24 / Updated on October 02, 2017 05:26